This inventor holds 3 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignee: Actelion Pharmaceuticals Ltd. Active years: 2022-2023.
Location History:
- Kasterlee, BE (2022)
- Beerse, BE (2023)
Company Filing History:
Years Active: 2022-2023
Title: Koen Torfs: Innovator in Pharmaceutical Composition
Introduction
Koen Torfs is a notable inventor based in Kasterlee, Belgium. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of pulmonary hypertension. With a total of 3 patents to his name, his work has the potential to impact many lives.
Latest Patents
Torfs' latest patents include a pharmaceutical composition comprising macitentan for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH). This invention focuses on high doses of macitentan and its use in the treatment and prevention of CTEPH. Additionally, he has developed a pharmaceutical composition for the treatment of pulmonary arterial hypertension (PAH), which also utilizes high doses of macitentan or aprocitentan.
Career Highlights
Koen Torfs is associated with Actelion Pharmaceuticals Ltd., where he has been instrumental in advancing research and development in the pharmaceutical sector. His innovative approaches to drug formulation and treatment methodologies have garnered attention in the medical community.
Collaborations
Some of his notable coworkers include Dénes Csonka and Hans Hoogkamer, who have collaborated with him on various projects within the pharmaceutical industry.
Conclusion
Koen Torfs stands out as a significant figure in pharmaceutical innovation, with his patents paving the way for new treatments in pulmonary hypertension. His contributions reflect a commitment to improving patient outcomes through scientific advancement.